Role of KCTD15 in Acute Myeloid Leukemia: Implications for Prognosis and Metabolic Regulation

ORIGINAL ARTICLE
Jiale Li, Zimu Wei

 
For citation: Li J, Wei Z. Role of KCTD15 in Acute Myeloid Leukemia: Implications for Prognosis and Metabolic Regulation. International Journal of Biomedicine. 2025;15(2):305-308. doi:10.21103/Article15(2)_OA6
 
Originally published June 5, 2025
 

Abstract: 

Background: Acute myeloid leukemia (AML) is a poor-prognosis malignancy with heterogeneous features. Despite current advances in revealing those features, the role of KCTD15 remains unclear.
Methods and Results: Clinical data and transcriptomic profiles from the TCGA-LAML cohort were obtained from The Cancer Genome Atlas (TCGA) and analyzed using the UCSC Genome Browser and UALCAN database. Patient prognoses were analyzed based on Kaplan-Meier survival curves and Log-rank tests. KCTD15 expression was significantly higher in APL compared to other AML subtypes. High expression of KCTD15 was associated with prolonged overall survival in AML patients.
Conclusion: KCTD15 is correlated with physiological characteristics and the outcome of AML and may be a potential indicator for evaluating AML prognosis.

Keywords: 
acute myeloid leukemia • KCTD15 • body weight • prognosis
References: 
  1. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM,  et al.. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 Sep 15;140(11):1200-1228. doi: 10.1182/blood.2022015850. PMID: 35767897; PMCID: PMC9479031.
  2. Cai SF, Levine RL. Genetic and epigenetic determinants of AML pathogenesis. Semin Hematol. 2019 Apr;56(2):84-89. doi: 10.1053/j.seminhematol.2018.08.001. Epub 2018 Aug 22. PMID: 30926095; PMCID: PMC8961685.
  3. Liu H. Emerging agents and regimens for AML. J Hematol Oncol. 2021 Mar 23;14(1):49. doi: 10.1186/s13045-021-01062-w. PMID: 33757574; PMCID: PMC7989091.
  4. Mohamed Jiffry MZ, Kloss R, Ahmed-Khan M, Carmona-Pires F, Okam N, Weeraddana P, Dharmaratna D, Dandwani M, Moin K. A review of treatment options employed in relapsed/refractory AML. Hematology. 2023 Dec;28(1):2196482. doi: 10.1080/16078454.2023.2196482. PMID: 37036019.
  5. Dikaiou P, Björck L, Adiels M, Lundberg CE, Mandalenakis Z, Manhem K, Rosengren A. Obesity, overweight and risk for cardiovascular disease and mortality in young women. Eur J Prev Cardiol. 2021 Oct 13;28(12):1351-1359. doi: 10.1177/2047487320908983. Epub 2020 Mar 2. PMID: 34647583.
  6. Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, Hill JO, Brancati FL, Peters A, Wagenknecht L; Look AHEAD Research Group. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011 Jul;34(7):1481-6. doi: 10.2337/dc10-2415. Epub 2011 May 18. PMID: 21593294; PMCID: PMC3120182.
  7. Kristensen DT, Nielsen LB, Jakobsen LHK, Kristensen TC, Jepsen LØ, Schöllkopf C, Theilgaard-Mönch K, El-Galaly TC, Roug AS, Severinsen MT. Effects of chemotherapy dose reductions in overweight patients with acute myeloid leukaemia: A Danish nationwide cohort study. Br J Haematol. 2022 Nov;199(4):539-548. doi: 10.1111/bjh.18448. Epub 2022 Sep 9. PMID: 36083781; PMCID: PMC9825846.
  8. Sano H, Fukushima K, Yano M, Osone S, Kato Y, Hasegawa D, Miyamura T, Iwamoto S, Takahashi H, Terui K, Tawa A, Tomizawa D. Analysis of overweight/obese pediatric patients with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 study. Int J Hematol. 2024 Jun;119(6):745-754. doi: 10.1007/s12185-024-03745-9. Epub 2024 Mar 9. PMID: 38460081.
  9. Wang J, Mei H, Chen W, Jiang Y, Sun W, Li F, Fu Q, Jiang F. Study of eight GWAS-identified common variants for association with obesity-related indices in Chinese children at puberty. Int J Obes (Lond). 2012 Apr;36(4):542-7. doi: 10.1038/ijo.2011.218. Epub 2011 Nov 15. PMID: 22083549.
  10. González JR, Estévez MN, Giralt PS, Cáceres A, Pérez LM, González-Carpio M, Ballester F, Sunyer J, Rodríguez-López R. Genetic risk profiles for a childhood with severe overweight. Pediatr Obes. 2014 Aug;9(4):272-80. doi: 10.1111/j.2047-6310.2013.00166.x. Epub 2013 Apr 29. PMID: 23629956.
  11. Zandoná MR, Sangalli CN, Campagnolo PD, Vitolo MR, Almeida S, Mattevi VS. Validation of obesity susceptibility loci identified by genome-wide association studies in early childhood in South Brazilian children. Pediatr Obes. 2017 Feb;12(1):85-92. doi: 10.1111/ijpo.12113. Epub 2016 Mar 23. PMID: 27005443.
  12. Coppola L, Baselice S, Messina F, Giannatiempo R, Farina A, Vitagliano L, Smaldone G, Salvatore M. KCTD15 Is Overexpressed in her2+ Positive Breast Cancer Patients and Its Silencing Attenuates Proliferation in SKBR3 CELL LINE. Diagnostics (Basel). 2022 Feb 25;12(3):591. doi: 10.3390/diagnostics12030591. PMID: 35328144; PMCID: PMC8947324.
  13. Angrisani A, Di Fiore A, De Smaele E, Moretti M. The emerging role of the KCTD proteins in cancer. Cell Commun Signal. 2021 May 17;19(1):56. doi: 10.1186/s12964-021-00737-8. PMID: 34001146; PMCID: PMC8127222.
  14. Smaldone G, Beneduce G, Incoronato M, Pane K, Franzese M, Coppola L, Cordella A, Parasole R, Ripaldi M, Nassa G, Soricelli A, Vitagliano L, Mirabelli P, Salvatore M. KCTD15 is overexpressed in human childhood B-cell acute lymphoid leukemia. Sci Rep. 2019 Dec 27;9(1):20108. doi: 10.1038/s41598-019-56701-7. PMID: 31882877; PMCID: PMC6934626.
  15. Buono L, Iside C, Pecoraro G, De Matteo A, Beneduce G, Penta de Vera d'Aragona R, Parasole R, Mirabelli P, Vitagliano L, Salvatore M, Smaldone G. A Comprehensive Analysis of the Expression Profiles of KCTD Proteins in Acute Lymphoblastic Leukemia: Evidence of Selective Expression of KCTD1 in T-ALL. J Clin Med. 2023 May 25;12(11):3669. doi: 10.3390/jcm12113669. PMID: 37297863; PMCID: PMC10253327.
  16. Tomczak K, Czerwińska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015;19(1A):A68-77. doi: 10.5114/wo.2014.47136. PMID: 25691825; PMCID: PMC4322527.
  17. Raney BJ, Barber GP, Benet-Pagès A, Casper J, Clawson H, Cline MS, Diekhans M, Fischer C, Navarro Gonzalez J, Hickey G, Hinrichs AS, Kuhn RM, Lee BT, Lee CM, Le Mercier P, Miga KH, Nassar LR, Nejad P, Paten B, Perez G, Schmelter D, Speir ML, Wick BD, Zweig AS, Haussler D, Kent WJ, Haeussler M. The UCSC Genome Browser database: 2024 update. Nucleic Acids Res. 2024 Jan 5;52(D1):D1082-D1088. doi: 10.1093/nar/gkad987. PMID: 37953330; PMCID: PMC10767968.
  18. Chandrashekar DS, Karthikeyan SK, Korla PK, Patel H, Shovon AR, Athar M, Netto GJ, Qin ZS, Kumar S, Manne U, Creighton CJ, Varambally S. UALCAN: An update to the integrated cancer data analysis platform. Neoplasia. 2022 Mar;25:18-27. doi: 10.1016/j.neo.2022.01.001. Epub 2022 Jan 22. PMID: 35078134; PMCID: PMC8788199.
  19. Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK, Varambally S. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017 Aug;19(8):649-658. doi: 10.1016/j.neo.2017.05.002. Epub 2017 Jul 18. PMID: 28732212; PMCID: PMC5516091.
  20. Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019 Feb;33(2):299-312. doi: 10.1038/s41375-018-0357-9. Epub 2019 Jan 16. PMID: 30651634; PMCID: PMC6365380.
  21. Salman H. Comparative Analysis of AML Classification Systems: Evaluating the WHO, ICC, and ELN Frameworks and Their Distinctions. Cancers (Basel). 2024 Aug 22;16(16):2915. doi: 10.3390/cancers16162915. PMID: 39199685; PMCID: PMC11352995.
  22. Moarii M, Papaemmanuil E. Classification and risk assessment in AML: integrating cytogenetics and molecular profiling. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):37-44. doi: 10.1182/asheducation-2017.1.37. PMID: 29222235; PMCID: PMC6142605.
  23. Galati PC, Ribeiro CM, Pereira LTG, Amato AA. The association between excess body weight at diagnosis and pediatric leukemia prognosis: A systematic review and meta-analysis. Blood Rev. 2022 Jan;51:100870. doi: 10.1016/j.blre.2021.100870. Epub 2021 Jul 22. PMID: 34384603.
  24. Tamaki M, Nakasone H, Nakamura Y, Kawamura M, Kawamura S, Takeshita J, Yoshino N, Misaki Y, Yoshimura K, Matsumi S, Gomyo A, Tanihara A, Kusuda M, Kameda K, Akahoshi Y, Kimura SI, Kako S, Kanda Y. Body Weight Loss Before Allogeneic Hematopoietic Stem Cell Transplantation Predicts Survival Outcomes in Acute Leukemia Patients. Transplant Cell Ther. 2021 Apr;27(4):340.e1-340.e6. doi: 10.1016/j.jtct.2021.01.006. Epub 2021 Jan 9. PMID: 33836885.
  25. Iijima M, Stall M, Wang L, Panetta JC, Triplett BM, Pui CH, Ribeiro RC, Rubnitz JE, Pounds SB, Inaba H. Changes in body mass index, weight, and height in children with acute myeloid leukemia and the associations with outcome. Blood Adv. 2022 May 10;6(9):2824-2834. doi: 10.1182/bloodadvances.2021006090. PMID: 35196375; PMCID: PMC9092412.
  26. Sung H, Siegel RL, Torre LA, Pearson-Stuttard J, Islami F, Fedewa SA, Goding Sauer A, Shuval K, Gapstur SM, Jacobs EJ, Giovannucci EL, Jemal A. Global patterns in excess body weight and the associated cancer burden. CA Cancer J Clin. 2019 Mar;69(2):88-112. doi: 10.3322/caac.21499. Epub 2018 Dec 12. PMID: 30548482.
  27. Nahmias-Blank D, Maimon O, Meirovitz A, Sheva K, Peretz-Yablonski T, Elkin M. Excess body weight and postmenopausal breast cancer: Emerging molecular mechanisms and perspectives. Semin Cancer Biol. 2023 Nov;96:26-35. doi: 10.1016/j.semcancer.2023.09.003. Epub 2023 Sep 20. PMID: 37739109.
  28. Avgerinos KI, Spyrou N, Mantzoros CS, Dalamaga M. Obesity and cancer risk: Emerging biological mechanisms and perspectives. Metabolism. 2019 Mar;92:121-135. doi: 10.1016/j.metabol.2018.11.001. Epub 2018 Nov 13. PMID: 30445141.
  29. Winter Y, Sankowski R, Back T. Genetic determinants of obesity and related vascular diseases. Vitam Horm. 2013;91:29-48. doi: 10.1016/B978-0-12-407766-9.00002-X. PMID: 23374711.
  30. Gutierrez-Aguilar R, Kim DH, Woods SC, Seeley RJ. Expression of new loci associated with obesity in diet-induced obese rats: from genetics to physiology. Obesity (Silver Spring). 2012 Feb;20(2):306-12. doi: 10.1038/oby.2011.236. Epub 2011 Jul 21. PMID: 21779089.
  31. Xu H, Shao J, Fang J, Yin B, Zhang L, Zhang J, Xia G. miR-381 Targets KCTD15 to Regulate Bovine Preadipocyte Differentiation In Vitro. Horm Metab Res. 2021 Jan;53(1):63-70. doi: 10.1055/a-1276-1602. Epub 2020 Nov 2. PMID: 33137828.
  32. Zhang FY, Wu L, Zhang TN, Chen HH. KCTD15 acts as an anti-tumor factor in colorectal cancer cells downstream of the demethylase FTO and the m6A reader YTHDF2. Commun Biol. 2024 Mar 4;7(1):262. doi: 10.1038/s42003-024-05880-9. PMID: 38438714; PMCID: PMC10912199.
  33. Smaldone G, Coppola L, Incoronato M, Parasole R, Ripaldi M, Vitagliano L, Mirabelli P, Salvatore M. KCTD15 Protein Expression in Peripheral Blood and Acute Myeloid Leukemia. Diagnostics (Basel). 2020 Jun 4;10(6):371. doi: 10.3390/diagnostics10060371. PMID: 32512747; PMCID: PMC7345863.
  34. Dutta S, Dawid IB. Kctd15 inhibits neural crest formation by attenuating Wnt/beta-catenin signaling output. Development. 2010 Sep;137(18):3013-8. doi: 10.1242/dev.047548. Epub 2010 Aug 4. PMID: 20685732; PMCID: PMC2926954.
  35. Smaldone G, Pirone L, Capolupo A, Vitagliano L, Monti MC, Di Gaetano S, Pedone E. The essential player in adipogenesis GRP78 is a novel KCTD15 interactor. Int J Biol Macromol. 2018 Aug;115:469-475. doi: 10.1016/j.ijbiomac.2018.04.078. Epub 2018 Apr 14. PMID: 29665387.
  36. Zhang P, Fu Y, Zhang R, Shang P, Zhang H, Zhang B. Association of KCTD15 gene with fat deposition in pigs. J Anim Physiol Anim Nutr (Berl). 2022 May;106(3):537-544. doi: 10.1111/jpn.13587. Epub 2021 Jun 9. PMID: 34106484.
  37. Dušátková L, Zamrazilová H, Aldhoon-Hainerová I, Sedláčková B, Včelák J, Hlavatý P, Bendlová B, Kunešová M, Hainer V. A common variant near BDNF is associated with dietary calcium intake in adolescents. Nutr Res. 2015 Sep;35(9):766-73. doi: 10.1016/j.nutres.2015.06.004. Epub 2015 Jun 16. PMID: 26162542.

Download Article
Received March 11, 2025.
Accepted April 24, 2025.
©2025 International Medical Research and Development Corporation.